Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Biohaven's BHV-7000?
BHV-7000 is a small molecule commercialized by Biohaven, with a leading Phase III program in Generalized Seizures;Partial Seizure. According to...
BHV-7000 by Biohaven for Bipolar I Disorder: Likelihood of Approval
BHV-7000 is under clinical development by Biohaven and currently in Phase III for Bipolar I Disorder. According to GlobalData, Phase...
BHV-7000 by Biohaven for Major Depressive Disorder: Likelihood of Approval
BHV-7000 is under clinical development by Biohaven and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase...
BHV-7000 by Biohaven for Partial Seizure: Likelihood of Approval
BHV-7000 is under clinical development by Biohaven and currently in Phase III for Partial Seizure. According to GlobalData, Phase III...
BHV-7000 by Biohaven for Generalized Seizures: Likelihood of Approval
BHV-7000 is under clinical development by Biohaven and currently in Phase III for Generalized Seizures. According to GlobalData, Phase III...